Toll Free: 1-888-928-9744

Alkermes Plc - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Alkermes Plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Alkermes Plc - Product Pipeline Review - 2014', provides an overview of the Alkermes Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alkermes Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Alkermes Plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Alkermes Plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Alkermes Plc's pipeline products

Reasons to buy

- Evaluate Alkermes Plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Alkermes Plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Alkermes Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Alkermes Plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alkermes Plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Alkermes Plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Alkermes Plc Snapshot 5
Alkermes Plc Overview 5
Key Information 5
Key Facts 5
Alkermes Plc - Research and Development Overview 6
Key Therapeutic Areas 6
Alkermes Plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Alkermes Plc - Pipeline Products Glance 13
Alkermes Plc - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Alkermes Plc - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Alkermes Plc - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Alkermes Plc - Drug Profiles 18
aripiprazole lauroxil 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
(samidorphan + buprenorphine hydrochloride) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
(samidorphan + olanzapine) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ALKS-7106 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ALKS-8700 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
samidorphan 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
(methylsamidorphan + opioid analgesic) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
olanzapine ER 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RDB-1419 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Alkermes Plc - Pipeline Analysis 30
Alkermes Plc - Pipeline Products by Target 30
Alkermes Plc - Pipeline Products by Route of Administration 31
Alkermes Plc - Pipeline Products by Molecule Type 32
Alkermes Plc - Pipeline Products by Mechanism of Action 33
Alkermes Plc - Recent Pipeline Updates 34
Alkermes Plc - Dormant Projects 41
Alkermes Plc - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
insulin human 42
r-hFSH 42
samidorphan 42
teriparatide 42
Alkermes Plc - Company Statement 43
Alkermes Plc - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48
List of Tables
Alkermes Plc, Key Information 5
Alkermes Plc, Key Facts 5
Alkermes Plc - Pipeline by Indication, 2014 7
Alkermes Plc - Pipeline by Stage of Development, 2014 8
Alkermes Plc - Monotherapy Products in Pipeline, 2014 9
Alkermes Plc - Combination Treatment Modalities in Pipeline, 2014 10
Alkermes Plc - Partnered Products in Pipeline, 2014 11
Alkermes Plc - Partnered Products/ Combination Treatment Modalities, 2014 12
Alkermes Plc - Pre-Registration, 2014 13
Alkermes Plc - Phase III, 2014 14
Alkermes Plc - Phase II, 2014 15
Alkermes Plc - Phase I, 2014 16
Alkermes Plc - Preclinical, 2014 17
Alkermes Plc - Pipeline by Target, 2014 30
Alkermes Plc - Pipeline by Route of Administration, 2014 31
Alkermes Plc - Pipeline by Molecule Type, 2014 32
Alkermes Plc - Pipeline Products by Mechanism of Action, 2014 33
Alkermes Plc - Recent Pipeline Updates, 2014 34
Alkermes Plc - Dormant Developmental Projects,2014 41
Alkermes Plc - Discontinued Pipeline Products, 2014 42
Alkermes Plc, Other Locations 46
Alkermes Plc, Subsidiaries 46 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify